// App-Quantinova.ai

e20026 : Neoadjuvant gefitinib for stage II-IIIA NSCLC with activating EGFR mutation (NCT01833572): an open-label, single-arm, phase II study.

Researchers

Presenter

  • Ranxia Gong

Principal Investigators

  • Haichuan Hu

  • Haiquan Chen

Medical Centers

  • Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China

  • Fudan University Shanghai Cancer Center, Shanghai, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Epidermal growth factor receptor

Drug/Treatment

  • gefitinib

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

Phase

  • II

Study Id's

  • NCT01833572

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved